Edward Christopher Dee: Quantifying the global deficit of LINACs
Authors: Fabio Y Moraes, Andre G Gouveia, Vanessa Freitas Bratti, Edward C Dee, Juliana Fernandes Pavoni, Laura M Carson, Cecília Félix Penido Mendes de Sousa, Richard Sullivan, Gustavo Nader Marta, Wilma M Hopman, Christopher M Booth, Ajay Aggarwal, Ahmedin Jemal, Timothy P Hanna, Brooke E Wilson, Gustavo Arruda Viani
“In the Lancet Oncology, The Lancet Group, led by Dr. Fabio Ynoe de Moraes, we present our latest manuscript, ‘Global linear accelerator requirements and personalised country recommendations: a cross-sectional, population-based study.’
In this study, we quantified the global deficit of LINACs. By 2045, we estimate that 30,470 LINACs will be needed globally to meet cancer care demands. Low-income countries (LICs) face the harshest deficits, with a median LSI of 1,523 compared to 96 in high-income countries.
Nearly 20% of countries have no radiotherapy access at all, leaving millions without this critical pillar of cancer treatment. Bridging this gap requires an estimated $123.9 billion.
Our work provides policymakers, healthcare systems, and global health organizations with a strategic framework to prioritize investments in radiotherapy workforce and infrastructure. Global collaboration is needed to ensure equitable access to cancer care worldwide.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023